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Abstract 
Background:  Influenza A virus is a leading causative pathogen of human acute respiratory infection. Recently, the 
co-circulation of pandemic (H1N1) 2009 and seasonal H3N2 viruses was reported, and sporadic cases with reassor-
tant avian H7N9 virus are continually reported in China. We aimed to establish a multiplex one-step real-time reverse 
transcription-polymerase chain reaction (rRT-PCR) assay to simultaneously detect and discriminate FluA subtypes, 
including human seasonal H3N2 virus, pandemic (H1N1) 2009 virus and reassortant avian H7N9 virus, in one reaction 
tube.
Methods: Clinical samples, including throat swabs and sputum, were collected from the patients with influenza-like 
illness (ILIs). Total viral RNA from each sample or viral culture was extracted, and the specific detection of FluA virus 
and its subtypes was performed using a multiplex rRT-PCR assay.
Results: The limitation of detection (LOD) of the multiplex assay was 5.4 × 10−2 50% tissue culture infective dose 
(TCID50) per reaction or 4.8 × 101 copies per reaction for each virus of the three viruses. For simultaneously detect-
ing the three viruses, the LOD was 1.8 × 10−2 TCID50 per reaction or 1.6 × 10 copies per reaction for testing the total 
FluA virus RNA and 5.6 × 10−2 TCID50 per reaction or 5.1 × 10 copies per reaction for the H3, H1, and H7 genes in one 
reaction tube. The multiplex assay specifically detected these viruses, and no cross-reaction with other pathogens was 
found. Moreover, the assay had reliable clinical sensitivity (100%) and valuable clinical specificity (>95%). The detection 
of FluA with the matrix (M) gene contributed to the further determination of these subtypes, and the Rnase P gene 
(RP) was considered an internal control to favourably evaluate the quality of the clinical samples.
Conclusions: These findings indicate that the multiplex assay can simultaneously detect and discriminate FluA 
subtypes with reliable sensitivity and specificity, which is required for the early clinical diagnosis and viral surveillance 
of patients with FluA infection.
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Background
Influenza A (Flu A) virus is the most widespread patho-
gen causing human respiratory infections, which is his-
torically associated with annual seasonal epidemics and 
influenza pandemics worldwide, such as those outbreaks 
in 1918, 1957, 1968, and 2009 (Cox and Subbarao 2000; 
Chen et  al. 2011; Bedford et  al. 2015). The human H1, 
H2, and H3 subtypes of the FluA viruses generally cause 
human infections. Recently, pandemic (H1N1) 2009 
emerged worldwide in 2009, and the human H3N2 out-
break in 2015 resulted in substantial human infections 
and deaths (Bedford et  al. 2015; Wu et  al. 2014; Davlin 
et  al. 2016; Yang et  al. 2015). Moreover, sporadic cases 
or outbreaks of the avian Flu A subtype, such as H5N1, 
H7N7, H10N8, and H9N2, have displayed direct trans-
mission from domestic poultry and/or wild birds to 
humans, especially the reassortant avian H7N9 virus 
from live poultry or avian outbreaks in China in 2013 
(Wu et al. 2014; Kudo et al. 2012; Kim et al. 2012; Koo-
pmans et  al. 2004; Chen et  al. 2013, 2014; Cheng et  al. 
2011; Ostrowsky et  al. 2012; Gao et  al. 2013). Most 
patients infected with these subtypes present similar 
symptoms with influenza-like illness (ILIs) in the early 
stages of disease, such as fever, fatigue and/or sore throat, 
severe acquired pneumonia, and even death.
Recently, the co-circulation of the pandemic (H1N1) 
2009 virus and the human H3N2 virus was reported, and 
patients infected with reassortant avian H7N9 virus have 
continuously increased in China (Bedford et  al. 2015; 
Davlin et  al. 2016; Yang et  al. 2015; Chong et  al. 2016). 
Thus, the early detection and diagnosis of the suspected 
cases is the most effective measure to control and pre-
vent further transmission of these FluA viruses (Chen 
et  al. 2011, 2013; Bedford et  al. 2015). Currently, high-
throughput and multiplex molecular techniques (poly-
merase chain reaction, PCR) for the detection of Flu A 
virus subtypes have been rapidly developed in many 
laboratories, as previously described (Chen et  al. 2011; 
Kang et  al. 2014; World Health Organization 2013). 
Therefore, we established a multiplex real-time reverse 
transcription-PCR (rRT-PCR) assay allowing the simulta-
neous detection and discrimination of the universal Flu A 
strains, pandemic (H1N1) 2009, human H3N2 and reas-
sortant avian H7N9 subtypes, and the Rnase P gene (RP) 
served as an internal control to monitor the quality of the 
clinical samples in one reaction tube.
Methods
Primer and probe design
The primers and probe of the FluA virus were designed 
based on the conserved regions of matrix (M) gene of 85 
FluA viruses, and the primers and probes of the human 
H3 gene of the human H3N2 virus, the human H1 gene 
of the pandemic (H1N1) 2009, and the H7 gene of the 
human with reassortant avian H7N9 virus infection were 
designed based on the highly conserved regions of the 
HA genes (26 H3N2, 27 H3N2, and 32 H7N9), which are 
available in the Global Initiative on Sharing Avian Influ-
enza Data (GISAID) and GenBank. The RP gene was 
used as an internal control to monitor the quality of the 
clinical specimen. The new primers and probes listed in 
Table  1 were synthesized by Sangon Biotech (Shanghai) 
Co., Ltd. (Shanghai, China). The referenced primers and 
probes from previous studies were also used for com-
parison with the multiplex assay in this study (Chen et al. 
2011; World Health Organization 2013).
Clinical samples
A total of 523 clinical specimens from the patients with 
ILIs, including 436 throat swabs and 87 sputum speci-
mens, were obtained from March 2014 to November 
2015 at the Infection Department, the First Affiliated 
Hospital, College of Medicine, Zhejiang University. All 
specimens were kept in viral transport medium sup-
plemented with penicillin (100 U/ml) and streptomycin 
(100 μg/ml) at −80 °C. The sample from each patient was 
divided into three tubes. The first was for viral detection, 
the second was for viral culture, and the last was stored. 
Informed consent was obtained from all individuals 
enrolled in this study, and the Ethics Committee of our 
hospital approved this study.
Virus isolation and total RNA or DNA extraction
Madin-Darby canine kidney (MDCK) cells were used 
for isolating the FluA virus by standard methods in a 
biosafety level-2 (BSL-2) laboratory for human H3N2 
virus and pandemic (H1N1) 2009, and a BSL-3 labo-
ratory was used for the reassortant avian H7N9 virus. 
Each fresh sample was inoculated with MDCK cells. 
When the cytopathogenic effect (CPE) of the FluA virus 
infected cells was observed, the cultured cells were har-
vested and clarified by low speed centrifugation (8000 g/
min). The harvested virus was detected by a PCR assay 
and certified by a sequence assay. The total viral RNA of 
the individual sample or the viral culture was extracted in 
50 μl of the elution buffer using the QIAamp Viral RNA 
Mini Kit (Qiagen, Valencia, CA) according to the manu-
facturer’s protocol, and the total DNA of the pathogens 
was extracted in 100  μl of the elution buffer using the 
QIAamp DNA Mini Kit (Qiagen, Valencia, CA) accord-
ing to the manufacturer’s protocol. The samples were 
stored at −70 °C.
Multiplex rRT‑PCR assay
The multiplex one-step rRT-PCR assay was performed 
by a one-step PrimeScript® RT-PCR reagent (Takara, 
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Dalian, China). The final optimised 50 μl reaction mixture 
consisted of 5 μl of RNA, 25 μl of 2× One Step RT-PCR 
Buffer, 1 μl of TaKaRa EX Taq HS (5 U/μl), 1 μl of Prime-
Script RT Enzyme Mix, 1 μl of forward primer (40 μM), 
1 μl of reverse primer (40 μM), 0.5 μl of probe (20 μM) 
for each virus, 0.8 μl of RP forward primer (40 μM), 0.8 μl 
of RP reverse primer (40 μM), 0.4 μl of RP probe (20 μM), 
and 6 μl of RNase-free water. The thermal cycling param-
eters were as follows: cDNA synthesis at 42 °C for 30 min; 
denaturation at 95 °C for 5 min; and 40 cycles at 95 °C for 
10 s; and 60  °C for 45 s. The fluorescence was recorded 
at 60 °C on an ABI 7500 real-time PCR system (Applied 
Biosystems, Foster City, CA).
Sensitivity and specificity
The titers of the three viruses were calculated by deter-
mining the 50% tissue culture infective dose (TCID50). 
The sensitivity of the multiplex assay was determined 
by testing tenfold serial dilutions of the human H3N2 
virus, the pandemic (H1N1) 2009 or reassortant avian 
H7N9 virus, or a mixture of the three viruses. Addition-
ally, the sensitivity of the multiplex assay was also evalu-
ated using tenfold serial dilutions of the RNA transcripts 
that were transcribed in vitro by a recombinant pGEM®-
Easy plasmid (Promega, Shanghai, China) and the 
RiboMAXTM Large Scale RNA Production System-SP6 
(Promega, Madison, Wisconsin, USA) according to the 
Table 1 Real-time RT-PCR primers and probes designed and used in this study
Flu A, universal influenza A virus; H1 (2009), pandemic [H1N1] 2009 virus; H3, seasonal H3N2 virus; H7, reassortant avian H7N9 virus; RP, Rnase P gene. HEX is 
hexachloro-fluorescein phosphoramidite; BHQ is Black Hole Quencher; ROX is carboxy-X-rhodamine; FAM is a proprietary fluorophore similar to 6-carboxyfluorescein 
fluorophore; CY5 is blue reporter dye xyanocyline; TAMRA is Carboxytetramethylrhodamine dye. The probe consisted of oligonucleotides with the 5′ reporter dye and 
the 3′ quencher dye
Primer and probe sets Sequences Gene target Location (bp) GenBank accession no.
Designed and used in this study
Flu A forward GGARTGGCTAAAGACAAGACCAATC Matrix protein 129–153
Flu A reverse GGCATTYTGGACAAAGCGTCTAC Matrix protein 227–249 KC885959.1
Flu A probe ROX-AGTCCTCGCTCACTGGGCACGGT-BHQ2 Matrix protein 199–221
(H1N1) 2009 forward GGAAAGAAATGCTGGATCTGGTA Hemagglutinin 822–844
(H1N1) 2009 reverse ATGGGAGGCTGGTGTTTATAGC Hemagglutinin 904–925 KP019929.1
(H1N1) 2009 probe TAMRA-TGCAATACAACTTGTCARACACCCGAAGG-BHQ2 Hemagglutinin 874–902
H3 forward GMAGCAAAGCCTACAGCAACT Hemagglutinin 269–289
H3 reverse GCCGGATGAGGCAACTAGTG Hemagglutinin 329–348 KP662684.1
H3 probe HEX-CTTATGATGTGCCGGATTATGCCTCCC-BHQ1 Hemagglutinin 296–322
H7 forward GAGGCRATGCAAAATAGAATACAGAT Hemagglutinin 1510–1535
H7 reverse CCGAAGCTAAACCARAGTATCACA Hemagglutinin 1569–1592 KC885956.1
H7 probe FAM-ACCCRGTCAAACTAAGCAGCGGYTAYAA-BHQ1 Hemagglutinin 1538–1565
RP forward AGATTTGGACCTGCGAGCG Ribonuclease P 50–68
RP reverse GAGCGGCTGTCTCCACAAGT Ribonuclease P 71–93 NM_006413.4
RP probe CY5-TTCTGACCTGAAGGCTCTGCGCG-BHQ2 Ribonuclease P 95–114
Designed in previous study and used in this study
Flu A forward GACCRATCCTGTCACCTCTGAC Matrix protein
Flu A reverse AGGGCATTYTGGACAAAKCGTCTA Matrix protein WHO (2013)(17)
Flu A probe FAM-TGCAGTCCTCGCTCACTGGGCACG-BHQ1 Matrix protein
H1 (2009) forward TGAGATATTCCCCAAGACAAGTTC Hemagglutinin
H1 (2009) reverse TTTGTAGAAGCTTTTTGCTCCAG Hemagglutinin Reference (2)
H1 (2009) probe FAM-TCATGACTCGAACAAAGGTGTAACGG-BHQ1 Hemagglutinin
H3 forward ACCCTCAGTGTGATGGCTTCCAAA Hemagglutinin
H3 reverse TAAGGGAGGCATAATCCGGCACAT Hemagglutinin Reference (2)
H3 probe CY5-ACGCAGCAAAGCCTACAGCAACTGT-BHQ2 Hemagglutinin
H7 forward AGAAATGAAATGGCTCCTGTCAA Hemagglutinin
H7 reverse GGTTTTTTCTTGTATTTTTATATGACTTAG Hemagglutinin WHO (2013)(17)
H7 probe FAM-AGATAATGCTGCATTCCCGCAGATG-BHQ1 Hemagglutinin
RP forward AGATTTGGACCTGCGAGCG Ribonuclease P
RP reverse GAGCGGCTGTCTCCACAAGT Ribonuclease P WHO (2013)(17)
RP probe FAM-TTCTGACCTGAAGGCTCTGCGCG-BHQ1- Ribonuclease P
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manufacturer’s protocol, as described previously (Chen 
et al. 2011; Kang et al. 2014).
The specificity of the multiplex assay was evaluated 
using the three viruses and their mixtures as well as a 
panel comprised of 18 other common respiratory path-
ogens (Seasonal H1N1 virus, influenza B virus, avian 
H5N1, avian H9N2, respiratory syncytial virus [types A 
and B], Enterovirus 71, Coxsackie A16, human rhinovi-
rus, Mycoplasma pneumoniae, Klebsiella pneumoniae, 
Acinetobacter baumannii, Pseudomonas aeruginosa, 
Staphylococcus aureus, Candida albicans, Neisseria men-
ingitides, human parainfluenza virus-2, and human ade-
novirus) at high concentrations (>104 TCID50, copies, 
or cells/ml). First, the three viruses and their mixtures 
were tested by the multiplex assay. Second, each nucleic 
acid (or their mixtures) of the 18 pathogens was tested by 
the multiplex assay. Third, the multiplex assay was used 
to test one or the three viruses, including one (or their 
mixtures) of the 18 pathogens. All of the pathogens were 
tested in triplicate by three independent runs using the 
multiplex assay and the rRT-PCR assay released by WHO 
and our previous study (Chen et al. 2011; World Health 
Organization 2013).
Detection of clinical specimens using multiplex rRT‑PCR 
assay
The clinical sensitivity and specificity were calculated 
using 523 clinical specimens that were blindly detected 
and compared using the multiplex assay, the referenced 
methods and tissue culture. For the positive, suspected or 
different results, the partially amplified DNA products of 
the positive sample were cloned into the pMD18T vec-
tor (Takara, Dalian, China) that was transformed into 
Escherichia coli, and their sequences were verified by a 
genomic sequence analysis performed at Sangon Biotech 
Co., Ltd. (Shanghai, China).
Results
Multiplex rRT‑PCR assay development and optimisation
The M gene and the HA gene sequences of 26 seasonal 
H3N2, 27 pandemic (H1N1) 2009, and 32 reassortant 
avian H7N9 viruses available from GISAID and GenBank 
were aligned and compared, respectively. A conserved 
region was selected to design the primer and probe sets 
for the M gene from these FluA subtypes, and a con-
served region was selected for the H3, H1 and H7 genes. 
These primers-probe sets were used to test the RNA of 
the corresponding FluA subtype at primer concentra-
tions of 0.2, 0.4, 0.8, 1.6, and 3.2 μM and probe concen-
trations ranging from 0.2 to 3.2  μM in a 50  μl reaction 
volume. The optimal concentration of the primers and 
the probe sets was 0.4 and 0.2  μM, respectively, for the 
M, H1, H3, H7, and RP genes (data not shown).
The final optimised 50 μl reaction mixture consisted of 
5 μl of RNA, 25 μl of 2× One Step RT-PCR Buffer, 1 μl 
of TaKaRa EX Taq HS (5 U/μl), 1  μl of PrimeScript RT 
Enzyme Mix, 1 μl of forward primer (40 μM) and 1 μl of 
reverse primer (40 μM), 0.5 μl of probe (20 μM) for each 
virus, 0.8 μl of RP forward primer (40 μM), 0.8 μl of RP 
reverse primer (40 μM), 0.4 μl of RP probe (20 μM), and 
6 μl of RNase-free water.
Sensitivity and specificity
The sensitivities and specificities of the multiplex rRT-
PCR assay as well as those of the referenced rRT-PCR 
methods were evaluated by analysing the serial dilutions 
of the three viruses and their related RNA transcripts. 
In our study, the original concentration of each of the 
three subtypes of FluA viruses (pandemic [H1N1] 2009, 
human H3N2 and reassortant avian H7N9 virus) was 
5.4 × 103 50% tissue culture infective dose (TCID50)/ml 
or 4.8 × 106 copies/ml. The limitation of detection (LOD) 
was 5.4 ×  10−2 TCID50 per reaction or 4.8 ×  10 copies 
per reaction for each virus subtype.
For the three mixed virus specimens, the final titer of 
each virus in 200  μl of the mixed virus specimens was 
1.8  ×  103 50% TCID50/ml, and the original mixture of 
the RNA transcripts for each FluA subtype was 1.6 × 106 
copies/ml. The LOD of the multiplex assay for simultane-
ous detecting the three mixed viruses was approximately 
1.8 ×  10−2 TCID50 per reaction or 1.6 ×  10 copies per 
reaction for total FluA virus and 5.6 × 10−2 TCID50 per 
reaction or 5.1 × 10 copies per reaction for the H3, H1, 
and H7 genes in one reaction tube.
As for the multiplex assay specificity, the multiplex 
assay specifically detected the three subtypes of FluA 
virus. We did not observe cross-reaction among the three 
types of viruses (pandemic [H1N1] 2009, human H3N2 
and reassortant avian H7N9 virus) or among the panel 
comprising the 18 other common respiratory patho-
gens at high concentrations (>104 TCID50, copies, or 
cells/ml), excluding the FluA gene in this study (Fig.  1). 
Additionally, the referenced rRT-PCR assay had a similar 
specificity for the three types of viruses.
Detection of clinical specimens
To further evaluate the clinical sensitivity and specific-
ity, each of the 523 clinical samples, including 436 throat 
swabs and 87 sputum specimens from the patients with 
ILIs, was inoculated into MDCK cells for influenza A 
virus isolation. The results showed that 125 samples were 
positive for FluA virus, including 28 pandemic (H1N1) 
2009, 88 human H3N2 and 9 reassortant avian H7N9 
samples. Compared with the cell culture, the analyses of 
the 523 samples by the multiplex rRT-PCR assay and ref-
erenced methods in parallel showed that 144 specimens 
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were positive for FluA, including 36 specimens with pan-
demic (H1N1) 2009 virus, 101 specimens with H3N2 
virus, and 9 specimens with reassortant avian H7N9 
virus (Table  2). Moreover, the results showed that the 
detection sensitivity for FluA, pandemic (H1N1) 2009, 
H3N2, and reassortant avian H7N9 virus was 100% (95% 
confidence interval [CI] 100–100%). The specificity was 
95.2% (95% CI 93.1–97.3%) for FluA virus, 98.4% (95% 
CI 97.3–99.5%) for pandemic (H1N1) 2009 virus, 97.0% 
(95% CI 95.4–98.6%) for H3N2 virus, and 100% (95% CI 
100–100%) for reassortant avian H7N9 virus. Addition-
ally, the results by the multiplex assay were fully com-
parable with the referenced rRT-PCR methods in this 
report.
Discussion
FluA virus is a negative-sense, single-stranded RNA 
virus that can be further classified into various subtypes 
according to two surface glycoproteins with hemagglu-
tinin (HA) and neuraminidase (NA) (Cox and Subbarao 
2000; Chen et  al. 2011). Sixteen H subtypes (H1–H16) 
and nine N subtypes (N1–N9) have been found in avian 
species, while the H17N10 and H18N11 subtypes have 
emerged in bats (Bedford et  al. 2015; Wu et  al. 2014; 
Fan et  al. 2014). Human infections with FluA viruses 
are commonly associated with the human H1, H2, and 
H3 subtypes that can cause outbreaks of FluA virus 
infection, such as the seasonal H3N2 virus and the pan-
demic (H1N1) 2009 virus (Cox and Subbarao 2000; Chen 
et al. 2011; Bedford et al. 2015; Davlin et al. 2016; Yang 
et al. 2015). However, sporadic cases or outbreaks of the 
avian FluA subtypes H5N1, H7N3, H10N8, and H9N2, 
and the reassortant avian H7N9 virus have resulted in 
the direct transmission from avians to humans and have 
caused many deaths in humans (Kudo et  al. 2012; Kim 
et al. 2012; Koopmans et al. 2004; Chen et al. 2013, 2014; 
Cheng et al. 2011; Ostrowsky et al. 2012; Gao et al. 2013). 
Most patients infected with these subtypes have mild 
symptoms during the early stages of the disease, such as 
acute respiratory infections associated with fever and/
or sore throat, with or without fatigue symptoms; how-
ever, the patients with H5N1 virus and reassortant avian 
H7N9 virus have a high mortality rate (Cheng et al. 2011, 
2013, 2014; Ostrowsky et al. 2012; Gao et al. 2013; Chong 
et al. 2016; Kang et al. 2014).
Currently, the pandemic (H1N1) 2009 virus and the 
human H3N2 virus infections are reported worldwide, 
and sporadic cases of reassortant avian H7N9 virus infec-
tion are continuously documented in China (Bedford 
et  al. 2015; Davlin et  al. 2016; Yang et  al. 2015; Chong 
et  al. 2016). It is well known that PCR, which is con-
ducted in many laboratories, is highly sensitive and spe-
cific for the detection of FluA virus and its subtypes (Cox 
and Subbarao 2000; Chen et al. 2011). High-throughput 
Fig. 1 Specificity of the multiplex rRT-PCR assay for pandemic (H1N1) 2009, H3N2, and reassortant avian H7N9 viruses. Signals from the RNA 
samples extracted from human pandemic (H1N1) 2009, seasonal H3N2, reassortant avian H7N9 virus (A/Zhejiang/DTID-ZJU01/2013), the clinical 
samples with negative FluA virus, and RP gene
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and multiplex rRT-PCR assay for the detection of Flu A 
virus subtypes has rapidly been established in many labo-
ratories (Chen et al. 2011; Kang et al. 2014; World Health 
Organization 2013). However, a multiplex rRT-PCR 
assay for the simultaneous detection of the human H3N2 
virus, the pandemic (H1N1) 2009 virus and the reassor-
tant avian H7N9 virus has not been reported. Therefore, 
there is an urgent need to establish a multiple and spe-
cific multiplex rRT-PCR assay, which is the most effec-
tive measure, for the early detection and confirmation 
of human H3N2 virus, pandemic (H1N1) 2009 virus and 
reassortant avian H7N9 virus to reduce the morbidity 
and mortality rates of patients with these viruses. Here, 
we developed a multiplex one-step rRT-PCR assay that 
simultaneously detected and discriminated the univer-
sal Flu A virus, the pandemic (H1N1) 2009, the human 
H3N2 and the reassortant avian H7N9 subtypes, and the 
Rnase P gene (RP) as an internal control in one reaction 
tube. The multiplex rRT-PCR assay had a reliable sensi-
tivity and specificity for the three viruses compared with 
the referenced rRT-PCR assay. Additionally, in this study, 
the LOD of the multiplex assay for the mixed viruses was 
slightly low but was high for the FluA virus compared to 
that of a single subtype of the FluA virus. For detecting 
a single subtype of virus, the LOD of the multiplex assay 
was the same as the referenced rRT-PCR assay. These 
results indicated that the simultaneous amplification of 
two or more types of virus may cause a lower LOD in the 
multiplex assay when using multiplex primers and probes 
in one reaction. Moreover, the pandemic (H1N1) 2009, 
human H3N2 and reassortant avian H7N9 viruses belong 
to the Flu A virus, and the slightly higher sensitivity of 
the multiplex assay for the FluA virus may be due to the 
simultaneous amplification of the three types of Flu A 
virus in one reaction.
The “gold standard” for the diagnosis of viral infection 
is considered to be tissue culture (Chen et al. 2013; Fan 
et al. 2014). To further evaluate the clinical sensitivity and 
specificity of the multiplex assay, each of the 523 clinical 
samples from the patients with ILIs was inoculated into 
MDCK cells for influenza A virus isolation, and the three 
viruses were detected by the multiplex assay and the ref-
erenced methods. The results of the multiplex assay were 
fully comparable with the referenced rRT-PCR methods 
in this report. However, there were two specimens with 
pandemic (H1N1) 2009 virus-H3N2 virus coinfections, 
and only H3N2 virus was cultured in the two specimens. 
Moreover, the two samples with coinfections were also 
confirmed by the multiplex assay, the referenced meth-
ods, and the genomic sequence analysis. Therefore, 
the two samples with coinfections were included in the 
sensitivity and specificity calculations. Additionally, the 
cycle threshold (Ct) values were all <32.0 using the mul-
tiplex assay and the referenced methods for each of the 
523 clinical samples, including the RP target gene. In 
this study, 19 specimens were negative by the viral iso-
lations but were positive by the PCR results, showing 
high Ct values (28.5–30.6), which indicated a low viral 
concentration. The discrepancy may have resulted from 
various factors. With a very low concentration of virus in 
the specimens, it can be difficult to generate a viral iso-
lation, or it may be possible that inhibitory components 
in the specimens prevent viral isolation in cell culture. 
Additionally, the competitive growth of two viruses in 
one sample may result in the isolation of only one virus 
in cell culture. To verify the positive results amplified by 
the multiplex assay, 12 positive samples with the H3N2 
virus, 8 positive samples with the pandemic (H1N1) 2009 
virus and 5 positive samples with the reassortant avian 
H7N9 virus were randomly selected to analyse their HA 
Table 2 Sensitivity and specificity of multiplex rRT-PCR assay for 523 clinical specimens
Values refer individually to the virus culture
Sens. sensitivity, Spec. specificity, 95% CI 95% confidence interval [CI]
a Nineteen negative samples by cell culture consisted of eight pandemic H1N1 (2009) b and eleven H3N2 virus c by PCR and genomic sequence analysis. 
Indeterminate results were excluded from sensitivity and specificity calculations
d Two patients with H1N1(2009) virus-H3N2 virus coinfections, one was identified in throat swab specimen from patient with kidney transplantation history, the 
other was detected in sputum specimen from patient with multiple myeloma history. However, there was only H3N2 virus cultured in the two patients specimens, 
respectively
Virus Culture Multiplex Reference Sens. (%) Spec. (%)
+ − + − + − (95% CI) (95% CI)
Flu A 125a 398 144 379 144 379 100 (100–100) 95.2 (93.1–97.3)
H1N1(2009) 28b 495 36 d 487 36e 487 100 (100–100) 98.4 (97.3–99.5)
H3N2 88c 435 101d 422 101e 422 100 (100–100) 97.0 (95.4–98.6)
H7N9 9 514 9 514 9 514 100 (100–100) 100 (100–100)
RP – 523 523 – 523 – 100 (100–100) 100 (100–100)
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genomic sequences that were confirmed by the Sangon 
Biotech Co., Ltd (Shanghai, China). These results strongly 
indicated that the multiplex rRT-PCR assay in the study 
was completely in accordance with the assay systems 
previously described (Chen et al. 2011; Kang et al. 2014; 
World Health Organization 2013; Fan et  al. 2014; Nie 
et al. 2013; Kuo et al. 2014).
Our study had several limitations. First, the multiplex 
rRT-PCR assay only evaluated three viruses and 18 other 
common respiratory pathogens. However, more respira-
tory pathogens should be enrolled in this study. Secondly, 
some important information (such as the drugs adminis-
tered) should be included, as certain drugs may affect the 
result of the detection and the tissue culture. Finally, the 
clinical sample population was relatively small in this study.
Conclusions
In conclusion, a sensitive and specific multiplex one-step 
rRT-PCR assay was developed for the early detection of 
most influenza A viruses and subtypes, including pan-
demic (H1N1) 2009, H3N2, and reassortant avian H7N9 
virus, in clinical samples from patients with ILIs. This 
multiplex assay will provide a rapid and easy method for 
clinical diagnostics and viral surveillance of influenza A 
and its subtypes.
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